Get the Stockscreener App
9.56
1.16%
0.11
After Hours:
9.56
Amicus Therapeutics Inc stock is traded at $9.56, with a volume of 3.68M.
It is up +1.16% in the last 24 hours and up +12.87% over the past month.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
See More
Previous Close:
$9.45
Open:
$9.42
24h Volume:
3.68M
Relative Volume:
0.76
Market Cap:
$2.95B
Revenue:
$571.16M
Net Income/Loss:
$-38.10M
P/E Ratio:
-78.04
EPS:
-0.1225
Net Cash Flow:
$-48.91M
1W Performance:
+0.84%
1M Performance:
+12.87%
6M Performance:
+50.79%
1Y Performance:
+0.63%
1-Day Range:
$9.31
$9.615
1-Week Range:
$9.27
$9.88
52-Week Range:
$5.51
$10.36
Amicus Therapeutics Inc Stock (FOLD) Company Profile
Name
Amicus Therapeutics Inc
Sector
Industry
Phone
(609) 662-2000
Address
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
9.56 | 2.92B | 571.16M | -38.10M | -48.91M | -0.1225 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-18-25 | Upgrade | Needham | Hold → Buy |
| Jul-17-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-13-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-06-24 | Initiated | Jefferies | Buy |
| May-30-24 | Initiated | Wells Fargo | Overweight |
| May-14-24 | Upgrade | Guggenheim | Neutral → Buy |
| Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| Apr-13-22 | Resumed | Goldman | Neutral |
| Jan-14-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Nov-15-21 | Upgrade | Stifel | Hold → Buy |
| Sep-30-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-19-21 | Resumed | BTIG Research | Buy |
| May-27-21 | Initiated | Needham | Hold |
| May-21-21 | Initiated | UBS | Buy |
| Apr-14-21 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-02-21 | Initiated | Stifel | Hold |
| Feb-12-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-28-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Downgrade | Citigroup | Buy → Neutral |
| Nov-11-20 | Initiated | Berenberg | Hold |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Feb-04-20 | Resumed | Cantor Fitzgerald | Overweight |
| Nov-12-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-19 | Initiated | H.C. Wainwright | Buy |
| Jun-05-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-05-19 | Initiated | Janney | Buy |
| Jan-30-19 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-29-18 | Initiated | Citigroup | Neutral |
| Aug-17-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
| Sep-13-17 | Reiterated | Chardan Capital Markets | Buy |
| Aug-10-17 | Reiterated | Chardan Capital Markets | Buy |
| Jan-24-17 | Upgrade | Robert W. Baird | Neutral → Outperform |
| May-18-16 | Initiated | BofA/Merrill | Buy |
| Apr-14-16 | Initiated | Robert W. Baird | Neutral |
| Apr-12-16 | Reiterated | Chardan Capital Markets | Buy |
| Sep-16-15 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jun-16-15 | Reiterated | Chardan Capital Markets | Buy |
View All
Amicus Therapeutics Inc Stock (FOLD) Latest News
Primecap Management Co. CA Sells 123,400 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
First Week of July 2026 Options Trading For Amicus Therapeutics (FOLD) - Nasdaq
Is Amicus Therapeutics Inc. stock supported by strong fundamentalsAnalyst Upgrade & Daily Stock Trend Reports - newser.com
Vise Technologies Inc. Takes Position in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Is Amicus Therapeutics Inc. stock attractive for growth ETFs2025 Price Momentum & Fast Momentum Entry Tips - newser.com
What insider trading reveals about Amicus Therapeutics Inc. stockTrade Entry Summary & Weekly High Momentum Picks - newser.com
Is Amicus Therapeutics Inc. stock attractive for ETFsInflation Watch & AI Forecasted Stock Moves - newser.com
Published on: 2025-11-20 05:57:54 - newser.com
What RSI levels show for Amicus Therapeutics Inc. (AM6) stockQuarterly Investment Review & Free Expert Approved Momentum Trade Ideas - newser.com
Is Amicus Therapeutics Inc. (AM6) stock vulnerable to rate hikesJuly 2025 Price Swings & Accurate Buy Signal Alerts - newser.com
Institutional scanner results for Amicus Therapeutics Inc.2025 Key Lessons & Weekly Breakout Stock Alerts - newser.com
Is Amicus Therapeutics Inc. trending in predictive chart modelsMarket Activity Recap & Free Fast Gain Swing Trade Alerts - newser.com
Is Amicus Therapeutics Inc. stock in correction or buying zone - newser.com
Why Amicus Therapeutics Inc. stock is a must watch in 20252025 Biggest Moves & Free Safe Capital Growth Stock Tips - newser.com
Is Amicus Therapeutics Inc. meeting your algorithmic filter criteria2025 Technical Patterns & Long-Term Safe Investment Plans - newser.com
Can Amicus Therapeutics Inc. stock maintain growth trajectoryMarket Performance Summary & Growth Focused Entry Reports - newser.com
Does Amicus Therapeutics Inc. stock trade at a discount to peers - newser.com
How forex fluctuations impact Amicus Therapeutics Inc. (AM6) stock2025 Breakouts & Breakdowns & Technical Pattern Recognition Alerts - newser.com
Is Amicus Therapeutics Inc. (AM6) stock good for long term investingShare Buyback & AI Enhanced Market Trend Forecasts - newser.com
Understanding Amicus Therapeutics Inc.’s price movement - newser.com
Is Amicus Therapeutics Inc. (AM6) stock nearing a technical breakoutJuly 2025 Retail & Free High Return Stock Watch Alerts - newser.com
Why Amicus Therapeutics Inc. (AM6) stock is trending on social media2025 Bull vs Bear & Growth-Oriented Investment Plans - newser.com
Published on: 2025-11-18 18:34:31 - newser.com
Published on: 2025-11-18 15:37:13 - newser.com
Amicus Therapeutics Shifts To Profit As Rare Disease Sales Climb - Finimize
How to manage a losing position in Amicus Therapeutics Inc.Weekly Trade Summary & Detailed Earnings Play Strategies - newser.com
Amicus Therapeutics Inc Stock (FOLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):